Holding out for a better upfront deal has paid off for bluebird bio investors to the tune of an additional $2.00 per share. Private equity firms Carlyle and SK Capital expect to complete the acquisition of bluebird on Monday. With
read moreA new partnership between the Chicago-based pharma and one of its hometown’s pro baseball teams will begin during Friday’s home game against the Cincinnati Reds. More: AbbVie flies the W against cancer with Chicago Cubs partnership, ASCO corporate campaign Source:
read moreIn the wake of sweeping cuts at the FDA’s Office of Prescription Drug Promotion, Sen. Dick Durbin, D-Ill., is questioning how effectively the agency can continue to regulate pharmaceutical advertisements. More: Senator grills Makary over FDA’s ability to regulate drug
read moreIn its first global phase 3 readout, Akeso and Summit Therapeutics’ closely watched PD-1xVEGF bispecific antibody ivonescimab significantly reduced the risk of progression or death by 48% in patients with previously treated EGFR-mutated nonsquamous non-small cell lung cancer. More: Akeso,
read moreAstellas is banging the drum for patient advocacy organizations again. One year after coordinating the first PAO Action Week, the Japanese drugmaker is gearing up for the second edition of an initiative designed to connect patients and caregivers with resources
read more© 1994 - 2026 B.M. Pharmaceuticals